Eagle Pharmaceuticals, Inc.
EGRX
$1.90
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 5.16M | 5.75M | 8.17M | -7.13M | -9.45M |
| Total Depreciation and Amortization | 5.90M | 5.89M | 5.96M | 4.18M | 1.94M |
| Total Amortization of Deferred Charges | 113.00K | 113.00K | 115.00K | 118.00K | 118.00K |
| Total Other Non-Cash Items | 2.93M | 2.78M | -5.79M | 14.06M | 5.68M |
| Change in Net Operating Assets | -14.23M | -48.05M | 29.11M | -24.46M | 44.71M |
| Cash from Operations | -126.00K | -33.51M | 37.56M | -13.24M | 42.99M |
| Capital Expenditure | -6.00K | -58.00K | -10.00K | 0.00 | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | 1.00K | 1.26M | -75.42M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -12.50M | 0.00 | -12.50M | -- |
| Cash from Investing | -6.00K | -12.56M | -9.00K | -11.24M | -75.42M |
| Total Debt Issued | 15.00M | 15.00M | 65.00M | 15.00M | -- |
| Total Debt Repaid | -21.25M | -1.25M | -61.24M | -2.00M | -2.00M |
| Issuance of Common Stock | -- | -- | 0.00 | 247.00K | 1.50M |
| Repurchase of Common Stock | -161.00K | -1.10M | -15.00K | -9.95M | -36.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -1.36M | -- | -- |
| Cash from Financing | -6.41M | 12.65M | 2.39M | 3.30M | -536.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -6.54M | -33.42M | 39.94M | -21.18M | -32.96M |